Karyopharm Announces Upcoming Virtual Investor Conference Participation
Karyopharm Therapeutics (Nasdaq: KPTI), a company focused on innovative cancer therapies, will have CEO Michael Kauffman participate in two virtual investor conferences. The SVB Leerink 10th Annual Global Healthcare Conference is scheduled for February 24, 2021, at 1:00 PM ET, while the Barclays Global Healthcare Conference will take place on March 9, 2021, at 9:10 AM ET. Live webcasts will be available on Karyopharm's website, with replays accessible for 30 days post-event.
- None.
- None.
NEWTON, Mass., Feb. 17, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at SVB Leerink's 10th Annual Global Healthcare Conference and at the Barclays Global Healthcare Conference. Details regarding these upcoming virtual investor conferences are below.
SVB Leerink 10th Annual Global Healthcare Conference
Date: Wednesday, February 24, 2021
Time: 1:00 PM Eastern Time
Barclays Global Healthcare Conference
Date: Tuesday, March 9, 2021
Time: 9:10 AM Eastern Time
A live webcast of the fireside chats can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. A replay of the webcast will be archived on the Company's website for 30 days following each fireside chat.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade® (bortezomib) and dexamethasone for the treatment of patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for NEXPOVIO® (selinexor) for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.
View original content:http://www.prnewswire.com/news-releases/karyopharm-announces-upcoming-virtual-investor-conference-participation-301230333.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
What conferences will Karyopharm's CEO participate in?
When is Karyopharm's participation in the SVB Leerink Conference?
When will the Barclays Global Healthcare Conference take place?
Where can I access the live webcast of Karyopharm's events?
How long will the webcasts be available for replay?
